Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Treatment of colorectal cancer (humanized monoclonal antibody hMN-14 targeting CEA- positive cancers).

Trademarks

CEA-CIDE (Immunomedics).

Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
ShangHai Biochempartner Co.,Ltd	17754423994 17754423994	2853530910@QQ.com	China	8011	62
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10457	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24644	58
Biolab Reagents	027-65279366 18108604862	products@biolabreagent.com	China	9818	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 13720134139	orders@jknbiochem.com	China	5825	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11974	58
Changsha Fuzhen Biotechnology Co.，LTD	18670069958 18670069958	3062105966@qq.com	China	3343	58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd	17316404525	209533805@qq.com	China	9909	58
Atagenix Laboratories	027-87008169 17762441161	info@atagenix.com	China	9848	58

---

• Immunoglobulin G,anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 g-chain), disulfide withhuman-mouse monoclonal hMN-14 k-chain, dimer
• Labetuzumab
• Research Grade Labetuzumab(DHC21001)
• IMMU-14|||hMN-14|||IMMU-100
• Research Grade Labetuzumab
• 219649-07-7